Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report.
Case report
hyperprogressive disease (HPD)
immune checkpoint inhibitors (ICIs)
pleural mesothelioma (PM)
Journal
Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
30
04
2024
accepted:
26
07
2024
medline:
21
10
2024
pubmed:
21
10
2024
entrez:
21
10
2024
Statut:
ppublish
Résumé
Use of immune checkpoint inhibitors (ICIs) is associated with new response types, such as hyperprogressive disease (HPD), whose definition is still being discussed. Some authors use dynamic indexes to define HPD. However, since the Checkmate-743 study, ICIs have been a first-line therapy for pleural mesothelioma (PM), thereby making use of dynamic indexes less appropriate. The aim of this study is to describe two cases of HPD and then discuss its definitions and implications. Herein, we report two cases of PM HPD on first-line ICI therapy. A 67-year-old man with right unresectable epithelioid PM, without HPD is a mode of progression for ICI-treated PM patients. Further investigation is needed to better define and anticipate HPD in these patients.
Sections du résumé
Background
UNASSIGNED
Use of immune checkpoint inhibitors (ICIs) is associated with new response types, such as hyperprogressive disease (HPD), whose definition is still being discussed. Some authors use dynamic indexes to define HPD. However, since the Checkmate-743 study, ICIs have been a first-line therapy for pleural mesothelioma (PM), thereby making use of dynamic indexes less appropriate. The aim of this study is to describe two cases of HPD and then discuss its definitions and implications.
Case Description
UNASSIGNED
Herein, we report two cases of PM HPD on first-line ICI therapy. A 67-year-old man with right unresectable epithelioid PM, without
Conclusions
UNASSIGNED
HPD is a mode of progression for ICI-treated PM patients. Further investigation is needed to better define and anticipate HPD in these patients.
Identifiants
pubmed: 39430317
doi: 10.21037/tlcr-24-382
pii: tlcr-13-09-2448
pmc: PMC11484718
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
2448-2452Informations de copyright
2024 AME Publishing Company. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-382/coif). C.C. received grants, funding support, consulting fees and support for attending meetings from AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer and Amgen. Jean-Bernard Auliac received grants, funding support, consulting fees and support for attending meetings from Boehringer Ingelheim, Hoffman-Roche, Takeda, BMS, MSD, Astra Zeneca, Amgen, Janssen and Pfizer. Jean-Baptiste Assie received funding support, consulting fees and support for attending meetings from BMS, GSK and Sanofi. The other authors have no conflicts of interest to declare.